Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now Dec 4, 2024 07:00AM
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now Jul 17, 2024 07:00AM
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now Jun 12, 2024 07:00AM
ATARA Biotherapeutics (ATRA) Announces 27.27M Share Direct Offering at $0.55/sh Jan 8, 2024 09:01AM
Atara Biotherapeutics Announces $15 Million Registered Direct Offering Jan 8, 2024 09:00AM
View Older Stories

Jan 8, 2024 08:00AM Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
Jan 4, 2024 04:01PM Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 20, 2023 04:01PM Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
Dec 11, 2023 12:01PM ATARA Biotherapeutics (ATRA) Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR
Dec 11, 2023 12:00PM Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
Dec 1, 2023 04:01PM Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 29, 2023 06:05PM Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
Nov 22, 2023 04:01PM Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
Nov 10, 2023 04:01PM Atara Biotherapeutics To Participate at the Stifel Healthcare Conference
Nov 8, 2023 05:37PM ATARA Biotherapeutics (ATRA) Reports Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188
Nov 8, 2023 05:35PM Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
Nov 1, 2023 08:30AM Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
Oct 6, 2023 04:01PM Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 19, 2023 04:01PM Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
Sep 1, 2023 04:01PM Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 31, 2023 04:01PM Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
Aug 8, 2023 04:01PM Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
Aug 4, 2023 04:01PM Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2023 04:01PM Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
Jul 31, 2023 04:01PM Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
Jul 7, 2023 04:01PM Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 7, 2023 04:01PM Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
Jun 5, 2023 09:00AM Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
Jun 2, 2023 04:01PM Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2023 04:01PM Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
May 5, 2023 04:01PM Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2023 04:01PM Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
Mar 31, 2023 04:01PM Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 3, 2023 04:01PM Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 1, 2023 04:01PM Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference
Feb 21, 2023 04:01PM Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
Feb 8, 2023 04:01PM Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
Feb 8, 2023 06:00AM Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecle
Feb 6, 2023 08:00AM Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
Feb 3, 2023 04:01PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 13, 2023 04:01PM Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jan 4, 2023 04:01PM Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 20, 2022 04:34PM ATARA Biotherapeutics (ATRA) Enters $31M Royalty Interest Financing Agreement with HealthCare Royalty
Dec 20, 2022 04:33PM Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
Dec 19, 2022 08:00AM Atara Biotherapeutics Announces Changes to Its Board of Directors
Dec 19, 2022 07:04AM ATARA's (ATRA) Ebvallo Approved in EU for Adults and Children with EBV+ PTLD
Dec 19, 2022 07:00AM Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
Dec 15, 2022 04:01PM Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dec 12, 2022 10:04AM ATARA Biotherapeutics (ATRA) Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
Dec 12, 2022 10:00AM Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
Dec 2, 2022 04:01PM Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 23, 2022 08:00AM Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
Nov 9, 2022 04:01PM Atara Biotherapeutics to Participate at the Stifel Healthcare Conference
Nov 8, 2022 04:01PM Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
Nov 4, 2022 04:01PM Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
View Older Stories